Three Molecular Barriers Block CNS Regeneration—And Single-Drug Approaches Keep Failing

The adult CNS actively blocks axon regeneration through myelin inhibitors, the glial scar, and developmental growth suppression. We know the molecular players. We have promising candidates in animal models. Yet clinical trials keep coming up short. The barriers are redundant—target one, the others remain. Combination therapy might be the only way forward.